Interleukin-1 and Tumor Necrosis Factor Alpha Induce Class 1 Aldehyde Dehydrogenase mRNA and Protein in Bone Marrow Cells

References

• Moreb J., Zucali J. R., Rueth S. The effects of tumor necrosis α on early human hematopoietic progenitor cells treated with 4-hydroperoxycyclophosphamide. Blood 1990; 76: 681–689
   PubMed Web of Science ®Google Scholar
• Moreb J., Zucali J. R., Gross M. A., Weiner R. S. Protective effects of IL-1 on human hematopoietic progenitor cells treated in vitro with 4-hydroperoxycyclophosphamide. J. Immunol. 1989; 142: 1937–1942
   PubMed Web of Science ®Google Scholar
• Zucali J. R., Moreb J., Bain C. Protection of cells capable of reconstituting long-term bone marrow stromal cultures from 4-hydroperoxycyclophosphamide by interleukin-1 and tumor necrosis factor α. Exp. Hematol. 1992; 20: 969–973
   PubMed Web of Science ®Google Scholar
• Moreb J., Zucali J. R., Zhang Y., Colvin M. O., Gross M. A. Role of aldehyde dehydrogenase in the protection of hematopoietic progenitor cells from 4-hydroperoxycyclophosphamide by IL-1 and TNF. Cancer Res. 1992; 52: 1770–1774
   PubMed Web of Science ®Google Scholar
• Russo J. E., Hauquitz D., Hilton J. Inhibition of mouse cytosolic aldehyde dehydrogenase by 4-(diethylamino)benzaldehyde. Biochem. Pharmacol. 1988; 37: 1639–1642
   PubMed Web of Science ®Google Scholar
• Zucali J. R., Broxmeyer H. E., Gross M. A., Dinarello C. Recombinant human tumor necrosis factors α and β stimulate fibroblasts to produce hemopoietic growth factors in vitro. J. Immunol. 1988; 140: 840–844
   PubMed Web of Science ®Google Scholar
• Arrick B. A., Nathan C. F. Glutathione metabolism as a determinant of therapeutic efficacy: a review. Cancer Res. 1984; 44: 4224–4232
   PubMed Web of Science ®Google Scholar
• Taylor Y. C., Brown J. M. Elevation of intracellular glutatione levels following depletion and its relationship to protection against radiation and alkylating agents. Pharmac. Ther. 1988; 39: 293–299
   PubMed Web of Science ®Google Scholar
• Sreerama L., Sladek N. E. Identification and characterization of a novel class 3 aldehyde dehydrogenase overexpressed in a human breast adenocarcinoma cell line exhibiting oxazaphosphorine-specific acquired resistance. Biochem. Pharmacol. 1993; 45: 2487–2505
   PubMed Web of Science ®Google Scholar
• Dockham P. A., Lee M-O., Sladek N. E. Identification of human liver aldehyde dehydrogenases that catalyze the oxidation of aldophosphamide and retinaldehyde. Biochem. Pharmacol. 1992; 43: 2453–2469
   PubMed Web of Science ®Google Scholar
• Chomezynski P., Sacchi N. Single step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. Anal. Biochem. 1987; 162: 156–159
   PubMed Web of Science ®Google Scholar
• Hsu L. C., Chang W-C., Yoshida A. Genomic structure of the human cytosolic aldehyde dehydrogenase gene. Genomics 1989; 5: 857–865
   PubMed Web of Science ®Google Scholar
• Sladek N. E., Landkamer G. J. Restoration of sensitivity to oxazaphosphorines by inhibitors of aldehyde dehydrogenase activity in cultured oxazaphosphorine-resistant P388 cell lines. Cancer Res. 1985; 45: 1549–1555
   PubMed Web of Science ®Google Scholar
• Kohn F. R., Sladek N. E. Aldehyde dehydrogenase activity as the basis for the relative insensitivity of murine pluripotent hematopoietic stem cells to oxazaphosphorines. Biochem. Pharmacol. 1985; 34: 3465–3471
   PubMed Web of Science ®Google Scholar
• Russo J. E., Hilton J. Characterization of cytosolic aldehyde dehydrogenase from cyclophosphamide-resistant L1210 cells. Cancer Res. 1988; 48: 1962–1968
   Web of Science ®Google Scholar
• Radin A. I., Zhoa X-L., Woo T. H., Colvin M. O., Hilton J. Structure and expression of the cytosolic aldehyde dehydrogenase gene in cyclophosphamide-resistant murine leukemia L1210 cells. Biochem. Pharmacol. 1991; 42: 1933–1938
   PubMed Web of Science ®Google Scholar
• Kastan M. B., Schlaffer E., Russo J. E., Colvin M. O., Civin C. I., Hilton J. Direct demonstration of elevated aldehyde dehydrogenase in human hematopoietic progenitor cells. Blood 1990; 75: 1947–1950
   PubMed Web of Science ®Google Scholar
• Ahmad S., Okine L., Le B., Najarian P., Vistica D. T. Elevation of glutathione in phenylalanine mustard-resistant murine L1210 leukemia cells. J. Biol. Chem. 1987; 262: 15048–15053
   PubMed Web of Science ®Google Scholar
• McGown A. T., Fox B. W. A proposed mechanism of resistance to cyclophosphamide and phosphoramide mustard in a Yoshida cell line in vitro. Cancer Chemother. Pharmacol. 1986; 17: 223–226
   PubMed Web of Science ®Google Scholar
• Green J. A., Vistica D. T., Young R. C., Hamilton I. C., Rogan A. M., Ozols R. F. Potentiation of melphalan cytotoxicity in human ovarian cancer cell lines by glutathione depletion. Cancer Res. 1984; 44: 5427–5431
   PubMed Web of Science ®Google Scholar
• Somfai-Relle S., Suzukake K., Vistica B. P., Vistica D. T. Reduction in cellular glutathione by buthionine sulfoximine and sensitization of murine tumor cells resistant to L-phenylalanine mustard. Biochem. Pharmacol. 1984; 33: 485–490
   PubMed Web of Science ®Google Scholar
• Kramer R. A., Greene K., Ahmad S., Vistica D. T. Chemosensitization of L-phenylalanine mustard by the thiolmodulating agent buthionine sulfoximine. Cancer Res. 1987; 47: 1593–1597
   PubMed Web of Science ®Google Scholar
• Andrews P. A., Murphy M. P., Howell S. B. Differential sensitization of human ovarian-carcinoma and mouse L2320 cells to cisplatin and melphalan by glutathione depletion. Mol. Pharmacol. 1980; 30: 643–650
   Google Scholar
• Ozols R. F., Louie K. G., Plowman J., Behrens B. C., Fine R. L., Dykes D., Hamilton T. C. Enhanced melphalan cytotoxicity in human ovarian cancer in vitro and in tumor-bearing nude mice by buthionine sulfoximine depletion of glutathione. Biochem. Pharmacol. 1987; 36: 147–153
   PubMed Web of Science ®Google Scholar
• Skapek S., Colvin O. M., Griffith O., Elion G. B., Bigner D. D., Friedman H. S. Enhanced melphalan cytotoxicity following butathione sulfoximine-mediated glutathione depletion in a human medulloblastoma xenograft in athymic mice. Cancer Res. 1988; 48: 2764–2767
   PubMed Web of Science ®Google Scholar
• Ozols R. F., Masuda H., Hamilton T. C. Keynote address: Mechanisms of cross-resistance between radiation and antineoplastic drugs. NCI Monogra. 1988; 6: 159–165
   PubMedGoogle Scholar
• Dulik D. M., Fenselan C., Hilton J. Characterization of melphalan-glutatione adducts whose formation is catalyzed by glutathione transferases. Biochem. Pharmacol. 1986; 35: 3405–3409
   PubMed Web of Science ®Google Scholar
• Gamesik M. P., Hamill T. G., Colvin M. NMR studies of the conjugation of mechlorethamine with glutathione. J. Med. Chem. 1990; 33: 1009–1014
   PubMed Web of Science ®Google Scholar
• Dulik D. M., Colvin O. M., Fenselan C. Characterization of glutathione conjugates of chloramucil by fast atom bombardment and thermospray liquid chromatography mass spectrometry. Biomed. Environ. Mass Spectrom. 1990; 19: 248–252
   PubMedGoogle Scholar
• Yuan Z. M., Fenselau C., Dulik D. M., Martin W., Emory W. B., Brundrett R. B., Colvin O. M., Cotter R. J. Laser desorption electron impact: application to a study of the mechanism of conjugation of glutathione and cyclophosphamide. Anal. Chem. 1990; 62: 868–870
   PubMed Web of Science ®Google Scholar
• Eastgate J., Moreb J., Nick H. S., Suzuki K., Taniguchi N., Zucali J. R. A role for manganese superoxide dismutase in radioprotection of hematopoietic stem cells by interleukin-1. Blood 1993; 81: 639–646
   PubMed Web of Science ®Google Scholar
• Masuda A., Longo D. L., Kobayashi Y., Appella E., Oppenheim J. J., Matsushima K. Induction of mitochondrial manganese superoxide dismutase by interleukin-1. J. FASEB 1988; 2: 3087–3091
   PubMed Web of Science ®Google Scholar
• Wong G. H. W., Goeddel D. V. Induction of manganese superoxide dismutase by tumor necrosis factor: Possible protective mechanism. Science 1988; 242: 941–944
   PubMed Web of Science ®Google Scholar
• Suresh A., Tung F., Moreb J., Zucali J. R. Role of manganese superoxide dismutase in radioprotection using gene transfer studies. Cancer Gene Therapy 1994; 1, (1), 85–90
   PubMed Web of Science ®Google Scholar
• Hirose K., Longo D. L., Oppenhem J. J., Matsushima K. Overexpression of mitochondrial manganese superoxide dismutase promotes the survival of tumor cells exposed to interleukin-1, tumor necrosis factor, selected anticancer drugs, and ionizing radiation. J. FASEB 1993; 7: 361–368
   PubMed Web of Science ®Google Scholar
• Schweder M., Suresh A., Zucali J., Tung F., Moreb J. Role of aldehyde dehydrogenase in the resistance to 4-hydroperoxycyclophosphamide using gene transfection. Exp. Hematol. 1994; 22, 701, Abs. 91
   Web of Science ®Google Scholar
• Stork L., Borczuk L., Kissinger M., Robinson W. Interleukin-1 accelerates murine granulocyte recovery following treatment with cyclophosphamide. Blood 1989; 73: 938–944
   PubMed Web of Science ®Google Scholar
• Castelli M., Black P., Schneider M., Pennington R., Abe F., Talmadge J. Protective, restorative and therapeutic properties of recombinant human IL-1 in rodent models. J. Immunol. 1988; 140: 3830–3837
   PubMed Web of Science ®Google Scholar
• Neta R., Oppenheim J. J. Cytokines in therapy of radiation injury. Blood 1988; 72: 1093–1095
   PubMed Web of Science ®Google Scholar
• Gallichio V. S. Accelerated recovery of hematopotesis following sub-lethal whole body irradiation with recombinant interleukin-1 (IL-1). J. Leuk. Biol. 1988; 43: 211–215
   PubMed Web of Science ®Google Scholar
• Neta R., Oppenheim J. J., Douches S. Interdependence of the radioprotective effects of IL-1, TNFα, G-CSF and murine recombinant GM-CSF. J. Immunol. 1988; 140: 108–111
   PubMed Web of Science ®Google Scholar
• Slordal L., Muench M. O., Warren D. J., Moore M. A. S. Radioprotection by murine and human tumor-necrosis factor: Dose-dependent effects on hematopoiesis in the mouse. Eur. J. Haematol. 1989; 43: 428–434
   PubMed Web of Science ®Google Scholar
• Neta R., Sztein M. B., Oppenheim J. J., Gillis S., Douches S. The in vivo effects of IL-1.1. Bone marrow cells are induced to cycle after administration of IL-1. J. Immunol. 1987; 139: 1861–1866
   PubMed Web of Science ®Google Scholar
• Warren E. J., Slordal L., Moore M. A. S. Tumor-necrosis factor induces cell cycle arrest in multipotential hematopoietic stem cells: a possible radioprotective mechanism. Eur. J. Haematol. 1990; 45: 158–163
   PubMed Web of Science ®Google Scholar
• Devary Y., Gottlieb R. H., Smeal T., Karin M. The mammalian ultraviolet response is triggered by activation of Sre tyrosine kinases. Cell 1992; 71: 1081–1091
   PubMed Web of Science ®Google Scholar
• Karin M., Herrlich P. Cis and transacting genetic elements responsible for induction of specific genes by tumor promoters, serum factors, and stress. Genes and Signal Transduction in Multistage Carcinogenesis, H. H. Coburn. Marcel Dekker, Inc, New York 1990; 415–440
   Google Scholar
• Holbrook J. J., Frenance H. J. Response to adversity: molecular control of gene activation following genotoxic stress. New Biol. 1991; 3: 825–833
   PubMedGoogle Scholar
• Zhou A., Elledge S. J. DUN1 encodes a protein kinase that controls the DNA damage response in yeast. Cell 1993; 75: 1119–1127
   PubMed Web of Science ®Google Scholar
• Engelberg D., Klein C., Martinetto H., Struhl K., Karin M. The UV response involving the Ras signaling pathway and AP-1 transcription factors is conserved between yeast and mammals. Cell 1994; 77: 381–390
   PubMed Web of Science ®Google Scholar
• Le J., Vilcek J. Tumor necrosis factor and interleukin-1: Cytokines with multiple overlapping biological activities. Lab. Invest. 1987; 56: 234–248
   PubMed Web of Science ®Google Scholar